SCHEMBL2471734

SCHEMBL2471734

O=C(CCc1ccc(F)cc1)N1CCC(C(=O)NCCc2ccc(Cl)cc2)(c2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.53
EPHX1 P07099 1/20 0.53
CHRM5 P08912 1/20 0.52
CHRM3 P20309 1/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
GFER P55789 1/20 0.48
MAPT P10636 1/20 0.48
TAAR1 Q96RJ0 1/20 0.47
CCR1 P32246 1/20 0.47
CCR3 P51677 1/20 0.47
DRD2 P14416 1/20 0.46
DRD4 P21917 1/20 0.46
DRD3 P35462 1/20 0.46
PLAAT3 P53816 2/20 0.46
PLAAT5 Q96KN8 2/20 0.46
PLAAT2 Q9NWW9 2/20 0.46
PLAAT4 Q9UL19 2/20 0.46
TP53 P04637 1/20 0.46
MDM2 Q00987 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2470233 0.92 OPRL1 (0.52) EPHX2EPHX1MEN1KMT2AGFER
SCHEMBL2469451 0.92 PLAAT3 (0.49) EPHX2EPHX1CHRM5CHRM3MEN1
SCHEMBL2471543 0.91 PLAAT3 (0.49) EPHX2EPHX1CHRM5CHRM3MEN1
SCHEMBL2468618 0.90 CHRM5 (0.54) EPHX2EPHX1CHRM5CHRM3MEN1
SCHEMBL2472649 0.90 CHRM5 (0.52) EPHX2CHRM5CHRM3MEN1KMT2A
SCHEMBL2517627 0.90 CHRM5 (0.54) EPHX2EPHX1CHRM5CHRM3MEN1
SCHEMBL13688315 0.88 CHRM5 (0.60) EPHX2EPHX1CHRM5CHRM3KMT2A
SCHEMBL2471846 0.88 CHRM5 (0.50) EPHX2CHRM5CHRM3MEN1KMT2A
SCHEMBL12194770 0.88 GFER (0.53) EPHX2CHRM5CHRM3KMT2AGFER
SCHEMBL2497408 0.87 CHRM5 (0.51) EPHX2CHRM5CHRM3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 EPHX2 3772/4885EPHX1 3117/4885CHRM5 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.